Theranostic 64Cu-DOTHA2-PSMA for metastatic prostate cancer treatment, a preclinical study

被引：0
|
作者：
Milot, M. C. [1 ]
Benesty, O. Belissant [1 ]
Dumulon-Perreault, V. [2 ]
Ait-Mohand, S. [1 ]
Rousseau, E. [1 ]
Richard, P. [3 ]
Guerin, B. [1 ]
机构：
[1] Univ Sherbrooke, Nucl Med & Radiobiol, Sherbrooke, PQ, Canada
[2] CRCHUS, Ctr Imagerie Mole Sherbrooke, Sherbrooke, PQ, Canada
[3] Univ Sherbrooke, Surg, Sherbrooke, PQ, Canada
来源：
EUROPEAN JOURNAL OF CANCER | 2020年 / 138卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
56
引用
收藏
页码：S24 / S24
页数：1
相关论文
共 50 条
  • [41] Experimental study of 68Ga/177Lu PSMA I&T: A novel PSMA inhibitor for theranostic of prostate cancer
    Zhang, Lulu
    Zhang, Pengjun
    Wang, Feng
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2019, 62 : S528 - S529
  • [42] Preclinical study of the PARP inhibitor ABT-888 in metastatic prostate cancer
    Zhang, Jingsong
    Mcgregor, Natalie
    Hussain, Maha H.
    Chinnaiyan, Arul
    CANCER RESEARCH, 2011, 71
  • [43] Lu-177-PSMA treatment for metastatic prostate cancer: case examples of major responses
    Kairemo, Kalevi
    Joensuu, Timo
    CLINICAL AND TRANSLATIONAL IMAGING, 2018, 6 (03) : 223 - 237
  • [44] The efficacy of Lu177-PSMA treatment at chemotherapy-naive metastatic prostate cancer
    Beytur, F.
    Sager, S.
    Bilgic, S.
    Nazari, A.
    Uslu-Besli, L.
    Asa, S.
    Sayman, H. B.
    Tural, D.
    Demirdag, C.
    Sonmezoglu, K.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S492 - S493
  • [45] Targeting prostate cancer with the anti-PSMA scFvD2B: a theranostic promise for nuclear medicine
    Carpanese, Debora
    Zorz, Alessandra
    Evangelista, Laura
    Salvarese, Nicola
    CLINICAL AND TRANSLATIONAL IMAGING, 2019, 7 (04) : 295 - 301
  • [46] Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review
    Patell, Kanchi
    Kurian, Matthew
    Garcia, Jorge A.
    Mendiratta, Prateek
    Barata, Pedro C.
    Jia, Angela Y.
    Spratt, Daniel E.
    Brown, Jason R.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (07) : 731 - 744
  • [47] Treatment of castration-resistant metastatic prostate cancer with [177Lu]PSMA radioligand
    Sundset, Rune
    Haugnes, Hege Sagstuen
    Perez, Alexander
    Engelsen, Ola
    Fosseide, Ida H. H.
    Castillejo, Miguel J.
    Bogsrud, Trond Velde
    TIDSSKRIFT FOR DEN NORSKE LAEGEFORENING, 2024, 144 (09)
  • [48] Myelotoxicity after Treatment with 177Lu-PSMA-617 in Patients with Metastatic Prostate Cancer
    Groener, D.
    Baumgarten, J.
    Davis, K.
    Happel, C.
    Mader, N.
    Ngoc, C. Nguyen
    Wichert, J.
    Mandel, P.
    Tselis, N.
    Gruenwald, F.
    Sabet, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S694 - S695
  • [49] 177Lu-PSMA for Extended Treatment of Metastatic Castration-Resistant Prostate Cancer
    Derlin, Thorsten
    Widjaja, Liam
    Werner, Rudolf A.
    Bengel, Frank M.
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (01) : 54 - 58
  • [50] Lu-177-PSMA treatment for metastatic prostate cancer: case examples of major responses
    Kalevi Kairemo
    Timo Joensuu
    Clinical and Translational Imaging, 2018, 6 : 223 - 237
12345